SCHEMBL17023015

SCHEMBL17023015

Cc1cccc(C)c1-c1ccc(OC(=O)Nc2ccc(N3CCN(C)CC3)nc2)c2nccnc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.54
RAB9A P51151 2/20 0.48
FGFR3 P22607 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.44
CYP1A2 P05177 1/20 0.42
EGFR P00533 2/20 0.41
PPARG P37231 1/20 0.40
GAA P10253 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
DGAT1 O75907 1/20 0.39
CCNT1 O60563 1/20 0.39
CDK4 P11802 1/20 0.39
CCND1 P24385 1/20 0.39
CDK9 P50750 1/20 0.39
CDK6 Q00534 1/20 0.39
CDK11A Q9UQ88 1/20 0.39
PDE7A Q13946 1/20 0.39
KDM4E B2RXH2 2/20 0.39
MAPT P10636 2/20 0.39
HSP90AA1 P07900 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17023116 0.86 L3MBTL1 (0.48) L3MBTL1RAB9AFGFR3SMN1; SMN2CYP1A2
SCHEMBL1126163 0.85 L3MBTL1 (0.67) L3MBTL1RAB9AFGFR3SMN1; SMN2CYP1A2
SCHEMBL17023125 0.85 L3MBTL1 (0.47) L3MBTL1RAB9AFGFR3SMN1; SMN2EGFR
SCHEMBL17023034 0.82 FGFR3 (0.49) L3MBTL1RAB9AFGFR3SMN1; SMN2EGFR
SCHEMBL17023016 0.81 FGFR3 (0.49) L3MBTL1RAB9AFGFR3SMN1; SMN2EGFR
SCHEMBL17023029 0.78 FGFR3 (0.50) RAB9AFGFR3SMN1; SMN2MAPT
SCHEMBL17023097 0.76 FGFR3 (0.59) FGFR3
SCHEMBL17023160 0.75 FGFR3 (0.80) FGFR3MAPT
SCHEMBL17023101 0.75 FGFR3 (0.64) FGFR3
SCHEMBL17023161 0.75 FGFR3 (0.61) RAB9AFGFR3SMN1; SMN2KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2282995-B1 DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS NOVARTIS AG (CH) 2015-08-26 EP claimed